Study: Radiologist Characteristics Predict Performance in Screening Mammography

Screening Mammography: According to a new study, by the Harvey L. Neiman Health Policy Institute and the American College of Radiology’s National Mammography Database Committee, the most influential radiologist characteristics impacting mammography interpretive performance were geography, breast sub-specialization, performance of diagnostic mammography, and performance of diagnostic ultrasound.

Published June 22 in Radiology, the study analyzed 11 years of screening mammography performance metrics from the National Mammography Database (NMD). From this dataset, researchers found that radiologists in the West or Midwest, breast subspecialists, and those who perform diagnostic mammography were more likely to achieve acceptable performance across a range of metrics. Those who perform breast ultrasound were less likely to achieve acceptable performance across metrics.

Researchers say that despite wide variation across radiologists in the accuracy of mammographic interpretation, factors that predict performance are poorly understood.

“It was interesting that in many cases certain characteristics predicted higher performance in some areas and, at the same time, lower performance on others,” said first author Cindy Lee, MD, FACMQ, FSBI, Assistant Professor of Radiology at NYU Grossman School of Medicine. For example, radiologists who are in academic practice, are breast imagers, and with more years in practice are more likely to have higher recall rates, but they are also more likely to detect higher proportions of ductal carcinoma in situ, have higher cancer detection rates, and higher invasive cancer detection rates — critical measures for reducing breast cancer mortality. “This example highlights the importance of assessing performance across measures holistically versus individual metrics in isolation, supporting guidance in the ACR BI-RADS atlas” Dr. Lee explained.

This study has the largest sample of radiologists with verified demographic and workforce data and interpretive screening performance in the United States. Of the 1,223 radiologists studied, 31.7% of radiologists had acceptable performance for all metrics, based on external benchmarks. For each metrics individually, 52-77% of radiologists demonstrated performance in the acceptable range.

“Most mammograms performed in the United States are interpreted by general radiologists and not by breast subspecialty radiologists, who account for less than 10% of all radiologists,” said Andrew Rosenkrantz, MD, MPA, lead study author, professor and Director of health policy in the Department of Radiology at NYU Grossman School of Medicine and a Neiman Institute senior affiliate research fellow. “As the U.S. population ages and greater numbers of women comply with screening guidelines, the demand for all radiologists to interpret screening mammograms is anticipated to increase. Hence, attention to the interpretive screening performance of all radiologists is critical, and strategies to improve interpretive accuracy among generalists would be beneficial.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version